VPC
LXEO icon

Vestal Point Capital’s Lexeo Therapeutics LXEO Stock Holding History

Vestal Point Capital’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$25.7M Hold
4,475,000
– – 0.72% 45
2025
Q4 		$44.4M Buy
4,475,000
+1,225,000
+38% +$11.2M 1.63% 21
2025
Q3 		$21.6M Buy
3,250,000
+21,839
+0.7% +$106K 0.98% 39
2025
Q2 		$13M Buy
3,228,161
+2,091,912
+184% +$6.88M 0.68% 42
2025
Q1 		$3.94M Sell
1,136,249
-63,751
-5% -$282K 0.28% 47
2024
Q4 		$7.9M Buy
1,200,000
+350,000
+41% +$2.76M 0.47% 46
2024
Q3 		$7.68M Buy
850,000
+10,000
+1% +$119K 0.61% 40
2024
Q2 		$13.5M Buy
840,000
+665,000
+380% +$9.66M 1% 30
2024
Q1 		$2.74M Buy
+175,000
New +$2.74M 0.23% 49

Other funds holding LXEO

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.71B AUM 374.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $141B AUM 30.34% 1-Year Est. Return
O
OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM